Please assess the completion status of the following clinical trial:

Trial Title: Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Germ cell tumors whatever histology (TGNS or séminoma : TGS ) whose origin is gonadic, extra-gonadic, retro-peritoneal or primitive mediastinal~2. Age \>= 18 years old~3. Histologically confirmed germ cell tumor (TGS) or biomarkers rate allowing to diagnose germ cell tumor without histology (TGNS)~4. Relapse or progression with bad prognosis in 1st treatment line : One of these criteria valid point 4 :~   progression after incomplete clinical response (Stable disease) to a Cisplatin basis chemotherapy; biomarker progression 4 weeks following the last chemotherapy cycle administration; progression during the first treatment line without obtention of at least stable disease; primitive mediastinal origin in first relapse.~5. TGNS or TGS in relapse after 2 treatment lines~6. Disease progression ( previous points 4 or 5) documented by :~   tumors biomarkers increase (AFP and/or HCG) if no, a biopsy is needed to confirm presence of tumors active cells~7. ECOG Performance status 0-2~8. Biological Function :~   Neutrophils \>= 1500/mm3, Platelets \>= 150.000/mm3 ; normal creatinine (or clearance \>= 50 ml/mn) ; SGOT, SGPT \<= 2,5N (or 5N if hepatic metastases), Bilirubin \< 1,5N~9. Cardiac Functions (FEV \>= 50%), Respiratory Functions , neurological Functions compatibles with high dose chemotherapy administration~10. Absence of previous intensification~11. Patient Information and Informed consent signature~12. HIV and B and C hepatitis negative serologies~13. Negative pregnancy test for women with reproductive potential and adequate contraception before study entry~14. Patient affiliated to social security system~Exclusion Criteria:~1. Patients whose diagnosis of relapse was not confirmed by an anatomopathological examination or by an increase of tumors markers~2. Primitive encephalic germ cell tumors~3. Germ cell tumors in relapse with favorable factors of treatment response to conventional chemotherapy (RC sustainable after Cisplatin): prior cRC or incomplete clinical response but with normalization of markers and testicular origin~4. Growing Teratoma lesions~5. Patients with HIV infection, hepatitis B and C~6. Patients with symptomatic brain metastases despite appropriate corticosteroid treatment~7. Associated pathology may prevent the patient to receive treatment, creatinine clearance ≤ 50 mL / min (calculated by Cockcroft-Gault)~8. FEV \<50%~9. History of cancer (except basal cell epithelioma skin cancer) in the 3 years preceding the entry into the trial~10. Patient already included in another clinical trial involving an experimental molecule~11. Pregnant or breast feeding women~12. Persons without liberty or under guardianship,~13. Geographical, social or psychological conditions that do not permit compliance with protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete